Literature DB >> 7851051

Future of prodrugs in antiviral therapy.

T Hasegawa1, T Kawaguchi.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7851051     DOI： 10.2165/00003088-199427050-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  20 in total

1.  Plasma concentrations of zidovudine in rats via oral administration of its ester prodrugs.

Authors:  T Kawaguchi; T Endoh; T Seki; K Juni
Journal:  J Pharm Sci       Date:  1991-04       Impact factor: 3.534

2.  Structural characterization of HIV reverse transcriptase: a target for the design of specific virus inhibitors.

Authors:  M Tisdale; B A Larder; D M Lowe; D K Stammers; D J Purifoy; P Ertl; C Bradley; S Kemp; G K Darby; K L Powell
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

Review 3.  Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

Authors:  R Yarchoan; H Mitsuya; C E Myers; S Broder
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

4.  A pro-drug of zidovudine with enhanced efficacy against human immunodeficiency virus.

Authors:  S R Gogu; S K Aggarwal; S R Rangan; K C Agrawal
Journal:  Biochem Biophys Res Commun       Date:  1989-04-28       Impact factor: 3.575

5.  Ester prodrugs of zidovudine.

Authors:  T Kawaguchi; K Ishikawa; T Seki; K Juni
Journal:  J Pharm Sci       Date:  1990-06       Impact factor: 3.534

6.  The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2'-ester prodrugs.

Authors:  Z Shao; G B Park; R Krishnamoorthy; A K Mitra
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

7.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

8.  Brain parenchymal metabolism of 5-iodo-2'-deoxyuridine and 5'-ester prodrugs.

Authors:  M K Ghosh; A K Mitra
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

9.  Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.

Authors:  Z Hao; D A Cooney; N R Hartman; C F Perno; A Fridland; A L DeVico; M G Sarngadharan; S Broder; D G Johns
Journal:  Mol Pharmacol       Date:  1988-10       Impact factor: 4.436

10.  Central nervous system targeting of 2',3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs.

Authors:  M E Morgan; S C Chi; K Murakami; H Mitsuya; B D Anderson
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191
View more
  1 in total

Review 1.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.